DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer

被引：0
|
作者：
Li, G. [1 ,2 ]
Su, P. [3 ]
Wang, S. [4 ]
Zhang, Y. [4 ]
Pang, J. [4 ]
Ou, Q. [4 ]
Shao, Y. [4 ]
Yu, H. [5 ]
Wang, X. [1 ,2 ]
机构：
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu, Peoples R China
[2] Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China
[3] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China
[4] Nanjing Geneseeq Technol Inc, Nanjing, Peoples R China
[5] Chengdu Jinniu Dist Peoples Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
DOT1L; Immune checkpoint inhibitors; Next-generation sequencing;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.21-17
引用
收藏
页码：S242 / S242
页数：1
相关论文
共 50 条
  • [41] Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer
    Yomota, Makiko
    Mirokuji, Kie
    Sakaguchi, Masahiro
    Kitahara, Yasuyuki
    Chin, Fangyi
    Setoguchi, Keigo
    Hosomi, Yukio
    INTERNAL MEDICINE, 2021, 60 (21) : 3459 - 3462
  • [42] Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer
    Feifei Wei
    Tetsuro Sasada
    Genes & Immunity, 2024, 25 : 89 - 91
  • [43] The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?
    Rassy, Elie
    Bakouny, Ziad
    Assi, Tarek
    Karak, Fadi El
    Pavlidis, Nicholas
    IMMUNOTHERAPY, 2019, 11 (10) : 913 - 920
  • [44] Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer
    Wei, Feifei
    Sasada, Tetsuro
    GENES AND IMMUNITY, 2024, 25 (01) : 89 - 91
  • [45] Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer
    Zeng, Yue
    Hu, Chun-Hong
    Li, Yi-Zheng
    Zhou, Jian-Song
    Wang, Shu-Xing
    Liu, Meng-Dong
    Qiu, Zhen-Hua
    Deng, Chao
    Ma, Fang
    Xia, Chun-Fang
    Liang, Fei
    Peng, Yu-Rong
    Liang, Ao-Xi
    Shi, Sheng-Hao
    Yao, Shi-Jiao
    Liu, Jun-Qi
    Xiao, Wen-Jie
    Lin, Xiao-Qiao
    Tian, Xin-Yu
    Zhang, Ying-Zhe
    Tian, Zhuo-Ying
    Zou, Ji-An
    Li, Yun-Shu
    Xiao, Chao-Yue
    Xu, Tian
    Zhang, Xiao-Jie
    Wang, Xiao-Ping
    Liu, Xian-Ling
    Wu, Fang
    NATURE MEDICINE, 2024, 30 (06) : 1680 - +
  • [46] Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?
    John, A.
    Popat, S.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 829 - 830
  • [47] The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression
    Ochi, Nobuaki
    Ichihara, Eiki
    Takigawa, Nagio
    Harada, Daijiro
    Inoue, Koji
    Shibayama, Takuo
    Hosokawa, Shinobu
    Kishino, Daizo
    Harita, Shingo
    Oda, Naohiro
    Hara, Naofumi
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 73 - 81
  • [48] Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non-small-cell lung cancer
    Rakaee, Mehrdad
    Tafavvoghi, Masoud
    Adib, Elio
    Ricciuti, Biagio
    Alessi, Joao Victor Machado
    Cortellini, Alessio
    Fulgenzi, Claudia A. M.
    Mollersen, Kajsa
    Bongo, Lars Ailo
    Hashemi, Sayed Ms
    Houda, Ilias
    Busund, Lill-Tove Rasmussen
    Donnem, Tom
    Bahce, Idris
    Pinato, David J. James
    Sholl, Lynette M.
    Awad, Mark M.
    Kwiatkowski, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] ENPEP as a potential predictor of immune checkpoint inhibitor efficacy
    Wang, Aoyun
    Chu, Han
    Jin, Zheng
    Gong, Zhihua
    Jia, Qingzhu
    Zhu, Bo
    CANCER MEDICINE, 2022, 11 (03): : 880 - 887
  • [50] The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations
    Sakamoto, Hiroaki
    Tanaka, Hisashi
    Shiratori, Toshihiro
    Baba, Keisuke
    Ishioka, Yoshiko
    Itoga, Masamichi
    Taima, Kageaki
    Hasegawa, Yukihiro
    Takanashi, Shingo
    Tasaka, Sadatomo
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 10 (06) : 610 - 614
12345